| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/JVI.78.2.922-929.2004 |
| P8608 | Fatcat ID | release_3mbrog26hvhgvhuiqqqweoxzji |
| P932 | PMC publication ID | 368845 |
| P698 | PubMed publication ID | 14694123 |
| P50 | author | David Dismuke | Q130228825 |
| P2093 | author name string | Jing Zhou | |
| Kuo-Hsiung Lee | |||
| Brett M Forshey | |||
| Christopher Aiken | |||
| Chin Ho Chen | |||
| Christopher Lundquist | |||
| Xiong Yuan | |||
| P2860 | cites work | HIV-1 infection of nondividing cells through the recognition of integrase by the importin/karyopherin pathway | Q24642513 |
| High-efficiency transformation of mammalian cells by plasmid DNA | Q27860469 | ||
| An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection | Q28331494 | ||
| Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation | Q28360742 | ||
| The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin-binding drug SDZ NIM 811 | Q28378949 | ||
| Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone | Q29547734 | ||
| Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene | Q29615351 | ||
| In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors | Q29620622 | ||
| A putative alpha-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly | Q33782377 | ||
| Association of Nef with the human immunodeficiency virus type 1 core | Q33821376 | ||
| Nef enhances human immunodeficiency virus type 1 infectivity resulting from intervirion fusion: evidence supporting a role for Nef at the virion envelope | Q33842252 | ||
| Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells | Q33845811 | ||
| A dominant block to HIV-1 replication at reverse transcription in simian cells | Q34161825 | ||
| Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication | Q34364648 | ||
| Nef-mediated downregulation of CD4 enhances human immunodeficiency virus type 1 replication in primary T lymphocytes | Q34999681 | ||
| Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. | Q39579012 | ||
| The spacer peptide between human immunodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity | Q39870242 | ||
| A quantitative assay for HIV DNA integration in vivo | Q40809319 | ||
| Anti-AIDS agents--XXVII. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives | Q41066416 | ||
| Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter | Q41070241 | ||
| Proteolytic processing and particle maturation | Q41100821 | ||
| Construction and in vitro properties of HIV-1 mutants with deletions in "nonessential" genes | Q41477153 | ||
| Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents | Q42555749 | ||
| p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents | Q45761377 | ||
| A sensitive and specific enzyme-based assay detecting HIV-1 virion fusion in primary T lymphocytes. | Q50498229 | ||
| Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication | Q73514585 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virion | Q1757347 |
| P304 | page(s) | 922-929 | |
| P577 | publication date | 2004-01-01 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation | |
| P478 | volume | 78 |
| Q42424208 | 3-O-(3',3'-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro |
| Q33326188 | A cell-penetrating helical peptide as a potential HIV-1 inhibitor |
| Q40410682 | A human immunodeficiency virus type 1 protease biosensor assay using bioluminescence resonance energy transfer |
| Q33220259 | A peptide inhibitor of HIV-1 assembly in vitro |
| Q34426498 | A role for microRNA-155 modulation in the anti-HIV-1 effects of Toll-like receptor 3 stimulation in macrophages |
| Q34771244 | A sensitive assay using a native protein substrate for screening HIV-1 maturation inhibitors targeting the protease cleavage site between the matrix and capsid |
| Q39917695 | A single amino acid substitution in a segment of the CA protein within Gag that has similarity to human immunodeficiency virus type 1 blocks infectivity of a human endogenous retrovirus K provirus in the human genome |
| Q24606079 | A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat |
| Q42546287 | A strongly transdominant mutation in the human immunodeficiency virus type 1 gag gene defines an Achilles heel in the virus life cycle |
| Q37336728 | A two-pronged structural analysis of retroviral maturation indicates that core formation proceeds by a disassembly-reassembly pathway rather than a displacive transition. |
| Q40074485 | Activation and inhibition of the proteasome by betulinic acid and its derivatives |
| Q27324263 | Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors |
| Q34552402 | Analysis of the N-terminal region of the murine leukemia virus nucleocapsid protein |
| Q24645221 | Anti-AIDS agents 69. Moronic acid and other triterpene derivatives as novel potent anti-HIV agents |
| Q33819240 | Anti-HIV-1 therapeutics: from FDA-approved drugs to hypothetical future targets |
| Q40262003 | Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a |
| Q40063752 | Betulinic acid derivatives that target gp120 and inhibit multiple genetic subtypes of human immunodeficiency virus type 1. |
| Q40370577 | Betulinic acid induces apoptosis in skin cancer cells and differentiation in normal human keratinocytes |
| Q34885660 | Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection |
| Q45428884 | Blocking HIV-1 virus assembly |
| Q28477791 | Characterization of a novel type of HIV-1 particle assembly inhibitor using a quantitative luciferase-Vpr packaging-based assay |
| Q47318968 | Conformation of gp120 determines the sensitivity of HIV-1 DH012 to the entry inhibitor IC9564. |
| Q36950909 | Contributions of Charged Residues in Structurally Dynamic Capsid Surface Loops to Rous Sarcoma Virus Assembly |
| Q45173552 | Determinants of activity of the HIV-1 maturation inhibitor PA-457. |
| Q34435796 | Development of a Novel Screening Strategy Designed to Discover a New Class of HIV Drugs |
| Q36523929 | Dimerization of the SP1 Region of HIV-1 Gag Induces a Helical Conformation and Association into Helical Bundles: Implications for Particle Assembly |
| Q27321347 | Distribution and Redistribution of HIV-1 Nucleocapsid Protein in Immature, Mature, and Integrase-Inhibited Virions: a Role for Integrase in Maturation |
| Q92623235 | Dominant Negative MA-CA Fusion Protein Is Incorporated into HIV-1 Cores and Inhibits Nuclear Entry of Viral Preintegration Complexes |
| Q30479297 | Electron cryotomography of immature HIV-1 virions reveals the structure of the CA and SP1 Gag shells |
| Q40979700 | FAITH - Fast Assembly Inhibitor Test for HIV. |
| Q37287731 | Fullerene Derivatives Strongly Inhibit HIV-1 Replication by Affecting Virus Maturation without Impairing Protease Activity |
| Q37115695 | GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro |
| Q24614498 | HIV type 1 Gag as a target for antiviral therapy |
| Q37447762 | HIV-1 Gag processing intermediates trans-dominantly interfere with HIV-1 infectivity. |
| Q38539565 | HIV-1 assembly, release and maturation. |
| Q34529834 | HIV-1 maturation inhibitor bevirimat stabilizes the immature Gag lattice |
| Q38549717 | HIV-1 protease inhibitor mutations affect the development of HIV-1 resistance to the maturation inhibitor bevirimat. |
| Q36857103 | Human immunodeficiency virus type 1 assembly, release, and maturation. |
| Q30478394 | Human immunodeficiency virus type 1 resistance to the small molecule maturation inhibitor 3-O-(3',3'-dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino acid substitutions at the CA-SP1 cleavage site in Gag |
| Q35992805 | Identification and Characterization of BMS-955176, a Second-Generation HIV-1 Maturation Inhibitor with Improved Potency, Antiviral Spectrum, and Gag Polymorphic Coverage. |
| Q57459053 | Identification of a Structural Element in HIV-1 Gag Required for Virus Particle Assembly and Maturation |
| Q35832693 | Identification of an HIV-1 Mutation in Spacer Peptide 1 That Stabilizes the Immature CA-SP1 Lattice. |
| Q28829072 | Identification of potent maturation inhibitors against HIV-1 clade C |
| Q37192174 | Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457) |
| Q30832180 | In vitro protease cleavage and computer simulations reveal the HIV-1 capsid maturation pathway |
| Q35139703 | In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat). |
| Q24599377 | In vitro selection of clinically relevant bevirimat resistance mutations revealed by "deep" sequencing of serially passaged, quasispecies-containing recombinant HIV-1 |
| Q38716274 | Inhibition of HIV-1 Maturation via Small-Molecule Targeting of the Amino-Terminal Domain in the Viral Capsid Protein |
| Q40357793 | Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles |
| Q37676344 | Insights into the activity of maturation inhibitor PF-46396 on HIV-1 clade C |
| Q42068006 | Interactions between SIVNef, SIVGagPol and Alix correlate with viral replication and progression to AIDS in rhesus macaques |
| Q27931628 | Investigation by atomic force microscopy of the structure of Ty3 retrotransposon particles |
| Q34045239 | Ionic derivatives of betulinic acid as novel HIV-1 protease inhibitors |
| Q59359572 | Maturation inhibitors facilitate virus assembly and release of HIV-1 capsid P224 mutant |
| Q28554482 | Mechanistic Studies and Modeling Reveal the Origin of Differential Inhibition of Gag Polymorphic Viruses by HIV-1 Maturation Inhibitors |
| Q82466284 | Molecular dynamics simulation studies of betulinic acid with human serum albumin |
| Q45421573 | Molecular factors required for human immunodeficiency virus type I infectivity |
| Q64247477 | Multiple Roles of HIV-1 Capsid during the Virus Replication Cycle |
| Q40894533 | Mutation of the SP1 sequence impairs both multimerization and membrane-binding activities of human immunodeficiency virus type 1 Gag. |
| Q39763774 | Mutations in the spacer peptide and adjoining sequences in Rous sarcoma virus Gag lead to tubular budding |
| Q36691642 | New betulinic acid derivatives for bevirimat-resistant human immunodeficiency virus type-1. |
| Q37450688 | New small-molecule inhibitor class targeting human immunodeficiency virus type 1 virion maturation |
| Q33624690 | Novel approaches to inhibiting HIV-1 replication. |
| Q37338985 | Other inhibitors of viral enzymes and functions |
| Q26771739 | Pharmacological intervention of HIV-1 maturation |
| Q24672964 | Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection |
| Q40750425 | Phenotypic susceptibility to bevirimat in isolates from HIV-1-infected patients without prior exposure to bevirimat |
| Q33864444 | Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat |
| Q21092230 | Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice |
| Q28469069 | Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol |
| Q27342743 | Protease cleavage leads to formation of mature trimer interface in HIV-1 capsid |
| Q41844750 | Protease-Mediated Maturation of HIV: Inhibitors of Protease and the Maturation Process |
| Q37411350 | Proteasome regulators: activators and inhibitors. |
| Q36967857 | Recent progress in antiretrovirals--lessons from resistance |
| Q90646261 | Resistance to Second-Generation HIV-1 Maturation Inhibitors |
| Q24795340 | Retroviruses 2004: review of the 2004 Cold Spring Harbor Retroviruses Conference |
| Q34387732 | Revisiting HIV-1 uncoating |
| Q40468585 | Role of HIV-2 envelope in Lv2-mediated restriction. |
| Q57799419 | Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial |
| Q92490664 | Second Generation Inhibitors of HIV-1 Maturation |
| Q35070372 | Simulated self-assembly of the HIV-1 capsid: protein shape and native contacts are sufficient for two-dimensional lattice formation |
| Q33769181 | Structural analysis of HIV-1 maturation using cryo-electron tomography |
| Q28485054 | Structural and functional insights into the HIV-1 maturation inhibitor binding pocket |
| Q28828191 | Structure-Activity Relationships of the Human Immunodeficiency Virus Type 1 Maturation Inhibitor PF-46396 |
| Q42202820 | Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1 |
| Q42021180 | Synthesis and Biological Evaluation of Macrocyclized Betulin Derivatives as a Novel Class of Anti-HIV-1 Maturation Inhibitors |
| Q30318499 | Synthesis, encapsulation and antitumor activity of new betulin derivatives |
| Q55517077 | The KT Jeang Retrovirology prize 2018: Eric Freed. |
| Q33727091 | The capsid-spacer peptide 1 Gag processing intermediate is a dominant-negative inhibitor of HIV-1 maturation |
| Q27009643 | The choreography of HIV-1 proteolytic processing and virion assembly |
| Q30440445 | The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain |
| Q24793247 | The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid |
| Q30437103 | The structural biology of HIV assembly |
| Q39630669 | Triterpene derivatives that inhibit human immunodeficiency virus type 1 replication |
| Q58388992 | Update on the development of HIV entry inhibitors |
| Q33774977 | Virtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid |
| Q24642446 | Virus maturation as a new HIV-1 therapeutic target |
Search more.